Mar. 31 at 9:33 PM
$TPST may look technically broken on the surface, but the bullish case starts with the idea that the stock is now deeply oversold and entering potential capitulation territory, where weak hands have largely exited. After a sharp breakdown below prior support, price is attempting to stabilize in the
$1.50–
$1.70 zone, which can act as a new base if buyers step in with volume. From a risk/reward standpoint, this is where speculative money typically looks for reversals, especially in biotech where sentiment can flip quickly on catalysts. Any reclaim of the
$1.80–
$2.00 range would be significant, as it would turn prior breakdown levels into a potential bear trap, opening the door for a squeeze toward
$2.40–
$2.50 (50-day moving average zone). With sentiment washed out, low expectations, and the possibility of clinical or partnership catalysts, TPST has the setup for a high-risk, high-reward bounce play, where even a modest shift in momentum could produce a move up
